Vertex Pharmaceuticals Inc.

VRTX

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (VX-993): Apr 2026. Short interest: 2.0% of float.

BiotechnologyCEO: Reshma KewalramaniIPO: 1991Website ↗

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Catalysts

Phase 2NegativeQ4 2008CethrinSpinal Cord InjuryNCT00500812

Primary: The primary goal of this study is to determine the safety and tolerability of Cethrin when administered in conjunction with fibrin sealant to the dura mater of the spinal cord. (Prestudy, 24-72 hrs, 6 weeks, 3, 6 & 12 months)Enrollment:48/48Sites: 8NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ1 2010TelaprevirHepatitis CNCT00535847

Primary: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment (24 weeks after the completion of treatment (up to Week 72))Enrollment:117/117Sites: 62NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2010telaprevirHepatitis CNCT00758043

Primary: Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24) (24 weeks after the last planned dose of study treatment)Enrollment:540/540Sites: 82RANDOMIZED, TREATMENT

Phase 2Q3 2013VX-222Chronic Hepatitis C VirusNCT01516918

Primary: The proportion of subjects who have a sustained virologic response at 12 weeks after the last planned dose of treatment (SVR12) (12 weeks)Enrollment:103/103Sites: 43NA, TREATMENT

Phase 3NegativeQ1 2014TelaprevirHepatitis CNCT01467479

Primary: Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12) (12 weeks after last planned dose of study drug (up to Week 60))Enrollment:185/185Sites: 59NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2014Lumacaftor Plus Ivacaftor CombinationCystic Fibrosis, Homozygous for the F508del CFTR MutationNCT01807923

Primary: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline, Week 16 and 24)Enrollment:559/559Sites: 89RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2014VX-135Chronic Hepatitis C, CHC, HCVNCT01842451

Primary: The safety and tolerability as assessed by adverse events (AEs), vital signs, 12-lead electrocardiograms (ECGs), echocardiograms, and laboratory assessments (Up to 64 weeks)Enrollment:23/23Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ2 2017Tezacaftor/IvacaftorCystic FibrosisNCT02508207

Phase 3ApprovedQ3 2017LUM/IVACystic FibrosisNCT02797132

Phase 2PositiveQ4 2017VX-150Acute PainNCT03206749

Primary: Time-weighted Sum of the Pain Intensity Difference (SPID) Between VX-150 Versus Placebo as Recorded on a Numeric Pain Rating Scale (NPRS) 0 to 24 Hours After the First Dose (0 to 24 hours after the first dose)Enrollment:243/243Sites: 4RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2018Tezacaftor/IvacaftorCystic FibrosisNCT02730208

Primary: Absolute Change in Total Brody/CF-CT Score (From Baseline at Week 72)Enrollment:41/41Sites: 9RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ4 2018VX-210Cervical Spinal Cord InjuryNCT02669849

Phase 2PositiveQ4 2020LUM/IVACystic FibrosisNCT03625466

Phase 3ApprovedQ4 2020TEZ/IVACystic FibrosisNCT03537651

Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Day 1 up to Week 100)Enrollment:130/130Sites: 55NA, TREATMENT

Phase 2NegativeQ4 2020VX-814Alpha 1-Antitrypsin DeficiencyNCT04167345

Primary: Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels (From Baseline at Day 28)Enrollment:48/48Sites: 28RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2021ELX/TEZ/IVACystic FibrosisNCT04353817

Phase 3Q4 2021LUMCystic FibrosisNCT03601637

Phase 2Q4 2021VX-147Glomerulosclerosis, Focal SegmentalNCT04340362

Phase 3PositiveQ2 2022ELX/TEZ/IVACystic FibrosisNCT04537793

Primary: Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites (From Day 1 through Day 15)Enrollment:83/83Sites: 22NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2023ELX/TEZ/IVACystic FibrosisNCT04545515

Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Baseline up to Week 100)Enrollment:120/120Sites: 34NA, TREATMENT

Phase 3PositiveQ3 2023ELX/TEZ/IVACystic FibrosisNCT05274269

Phase 2Q3 2024ALPN-101Systemic Lupus ErythematosusNCT04835441

Phase 2Q2 2025VX-993Acute PainNCT06619847

Phase 3Q4 2025CTX001Beta-Thalassemia, Thalassemia, Genetic Diseases, InbornNCT03655678

Primary: Proportion of participants achieving transfusion independence for at least 12 consecutive months (TI12) (From 60 days after last RBC transfusion up to 24 months post-CTX001 infusion])Enrollment:59/59Sites: 14NA, TREATMENT

Phase 2Q2 2026VX-522 mRNA therapyCystic FibrosisNCT05668741

Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 Through Week 8 [SAD and MAD])Enrollment:26/26Sites: 26NA, TREATMENT

Phase 2Q2 2026VX-993Diabetic Peripheral Neuropathic PainNCT06619860

Primary: Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 (From Baseline up to Week 12)Enrollment:Target 300Sites: 47RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2026VX-264Type 1 DiabetesNCT05791201

Primary: Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 up to 24 months)Enrollment:7/7Sites: 16NA, TREATMENT

Phase 3Q2 2026CTX001Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea IntoleranceNCT05329649

Primary: Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12) (Up to 24 Months After CTX001 Infusion)Enrollment:13/13Sites: 7NA, TREATMENT

Phase 3Q2 2026CTX001Beta-Thalassemia, Thalassemia, Genetic Diseases, InbornNCT05356195

Primary: Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12) (Up to 24 Months After CTX001 Infusion)Enrollment:16/16Sites: 6NA, TREATMENT

Phase 2Q3 2026PovetaciceptIdiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic AnemiaNCT05757570

Primary: Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs) (Study Day 1 through 30 days after last dose of study drug)Enrollment:30/30Sites: 44NON_RANDOMIZED, TREATMENT

Phase 3Q3 2026Biological/VaccineType 1 Diabetes, Kidney TransplantNCT06832410

Primary: Proportion of Participants who are Insulin Independent (At 1 year After VX-880 infusion)Enrollment:Target 10Sites: 7NA, TREATMENT

Phase 3Q4 2026VX-121/TEZ/D-IVACystic FibrosisNCT05444257

Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Baseline up to Week 148)Enrollment:822/822Sites: 195NA, TREATMENT

Phase 3Q1 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT06696443

Primary: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Baseline up to Week 54)Enrollment:455/455Sites: 65NA, TREATMENT

Phase 2Q1 2027VX-670Myotonic Dystrophy Type 1 (DM1)NCT06185764

Primary: Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) (Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168)Enrollment:47/47Sites: 26RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT07231419

Primary: Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo (From Baseline up to Week 12)Enrollment:Target 734Sites: 75RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2027ELX/TEZ/IVACystic FibrosisNCT05331183

Primary: Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Day 1 up to Week 196)Enrollment:297/297Sites: 81NA, TREATMENT

Phase 3Q2 2027SuzetrigineDiabetic Peripheral Neuropathic PainNCT06628908

Phase 3Q2 2027CTX001Beta-Thalassemia, Thalassemia, Hematologic DiseasesNCT05477563

Phase 2Q3 2027VX-407Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT07161037

Phase 3Q3 2027ELX/TEZ/IVACystic FibrosisNCT06460506

Phase 3Q4 2027VX-880Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe HypoglycemiaNCT04786262

Phase 3Q1 2028PovetaciceptImmunoglobulin A NephropathyNCT06564142

Phase 3Q2 2028VX-147Proteinuric Kidney DiseaseNCT05312879

Phase 3Q4 2028PovetaciceptPrimary Membranous NephropathyNCT07204275

Phase 2Q1 2029VX-670Myotonic Dystrophy Type 1 (DM1)NCT06926621

Phase 2Q1 2029PovetaciceptMyasthenia Gravis, GeneralizedNCT07501702

Phase 3Q3 2029VNZ/TEZ/D-IVACystic FibrosisNCT05844449

Phase 3Q4 2029PovetaciceptImmunoglobulin A NephropathyNCT07807995

Phase 3Q2 2030VX-121/TEZ/D-IVACystic FibrosisNCT05422222

Phase 3Q4 2033Exa-celSickle Cell DiseaseNCT05951205

Phase 3Q3 2039CTX001Beta-Thalassemia, Thalassemia, Sickle Cell DiseaseNCT04208529

Recent News & Research

PubMed

Physiologically Based Pharmacokinetic Modeling of Elexacaftor-Tezacaftor-Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events.

# Investment Summary: VRTX CF Therapy Safety Analysis This PBPK modeling study investigates potential brain exposure of Vertex's triple combination CF therapy (Trikafta) and its relationship to reported neuropsychiatric adverse events—a safety signal that could impact label expansion, pediatric uptake, and commercial positioning. The research addresses a clinically relevant gap by quantifying CNS penetration across adult and pediatric populations, which may inform risk mitigation strategies and regulatory discussions around dose optimization or patient monitoring protocols. Clarifying the mechanism behind neuropsych events could either validate current safety practices, support market expansion into younger populations, or necessitate clinical modifications that affect competitive differentiation in the growing CF modulator market.

Oct 9, 2026

PubMed

Lung transplant perspectives in the era of elexacaftor/tezacaftor/ivacaftor (ETI): Navigating clinical uncertainty and ETI limbo among people with cystic fibrosis, a qualitative analysis.

# Investment Summary: VRTX ETI (Trikafta) and CF Lung Transplant Market This qualitative study examines clinical decision-making uncertainty among CF patients and physicians regarding lung transplantation eligibility in the context of ETI (Trikafta) therapy, highlighting a gap between dramatically improved survival outcomes and traditional transplant referral timing. The research suggests potential commercialization challenges for Trikafta, as physicians and patients face ambiguity about when disease progression warrants transplant listing when ETI can substantially delay or prevent transplant need. For investors, this reveals a critical market dynamic: while Trikafta expands its addressable population by deferring end-stage CF disease, it may compress long-term transplant-dependent patient cohorts, potentially affecting downstream orphan drug economics and creating reimbursement/clinical guideline pressures as payers reassess CF disease management strategies.

Oct 8, 2026

PubMed

Suzetrigine as Part of Multimodal Therapy Enables Opioid-Free Recovery after Laparoscopic or Arthroscopic Procedures.

# Vertex Pharmaceuticals (VRTX) - Research Summary **Clinical Finding:** A 2026 study demonstrates that suzetrigine, a selective sodium channel inhibitor in Vertex's pipeline, enables opioid-free pain management when combined with other analgesics following minimally invasive surgical procedures, suggesting potential for reducing opioid dependence in the acute post-operative setting. **Investment Implications:** This multimodal efficacy data strengthens suzetrigine's commercial positioning in acute pain—a large market with significant unmet need for opioid alternatives—and could support label expansion beyond chronic pain indications, potentially improving peak sales forecasts and market differentiation versus competitors' pain assets.

Oct 1, 2026

PubMed

Response to Bradshaw et al "Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker.".

# Investment Summary: Vertex's Suzetrigine Program This appears to be a correspondence/response piece regarding Vertex's phase 2 suzetrigine trial in acute pain, rather than new primary clinical data. The relevance for investors depends on whether the response addresses efficacy concerns, safety signals, or competitive positioning—key factors that will influence suzetrigine's commercial viability in the competitive acute pain market where opioid alternatives face high regulatory scrutiny. **Key investor consideration:** Suzetrigine's clinical profile relative to existing analgesics and development timeline will determine whether this differentiated NaV1.8 mechanism can capture meaningful market share, particularly given recent FDA skepticism toward non-opioid pain therapies requiring new clinical trials. *Note: A full article review would be needed to assess specific implications for VRTX's pipeline and competitive positioning.*

Oct 1, 2026

PubMed

Autoinduction and suzetrigine: potential clinical implications.

I don't have access to the specific article you're referencing (published October 2026), so I cannot provide an accurate summary of its findings or clinical implications for suzetrigine. To give you a meaningful investment analysis, I would need either: - The abstract or full text of the article - Key data points (efficacy results, trial outcomes, safety findings) - Clinical trial phase and indication details If you can share those details, I can provide a focused 2-3 sentence summary highlighting the commercial and clinical significance for VRTX's pipeline. Alternatively, I'd recommend checking Vertex's latest earnings calls, press releases, or clinical trial databases (ClinicalTrials.gov) for the most current information on suzetrigine development status.

Oct 1, 2026

Vertex Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research